A PHASE 3, MULTICENTER, MULTINATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED INDUCTION AND MAINTENANCE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-93538 IN ADULT AND ADOLESCENT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS

Registry ID

CC-93538-EE-001

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

BRISTOL-MYERS SQUIBB CANADA

Start date

2021-07-09

Last update

2021-04-07

Conditions

• EOSINOPHILIC ESOPHAGITIS

Related clinical trials

• A PHASE 4, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PARALLEL-GROUP, 24 WEEKS, PLACEBO-CONTROLLED STUDY FOLLOWED BY 104 WEEKS OPEN-LABEL TO ASSESS DUPILUMAB EFFICACY ON ESOPHAGEAL FUNCTION AND REMODELING IN ADULT PARTICIPANTS WITH EOSINOPHILIC ESOPHAGITIS (EOE)
• A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED PHASE III EFFICACY AND SAFETY STUDY OF TEZEPELUMAB IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS (CROSSING)
• A PHASE 1B/2A, OPEN LABEL TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS, AND EFFICACY OF EP-104IAR IN ADULTS WITH EOSINOPHILIC ESOPHAGITIS (RESOLVE)
• DOUBLE-BLIND, DOUBLE-DUMMY, RANDOMIZED, PARALLEL-GROUP, NON-INFERIORITY PHASE III TRIAL ON THE EFFICACY AND TOLERABILITY OF 2 MG ONCE DAILY VS. 1 MG TWICE DAILY BUDESONIDE ORODISPERSIBLE TABLETS FOR INDUCTION OF HISTOLOGICAL REMISSION IN ADULTS WITH EOSINOPHILIC ESOPHAGITIS
• A PHASE 3, MULTICENTER, MULTINATIONAL, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF CC-93538 IN ADULT AND ADOLESCENT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN PEDIATRIC PATIENTS WITH ACTIVE EOSINOPHILIC ESOPHAGITIS

View on source registry